VKTX — Viking Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $2.81bn
- $1.95bn
Annual balance sheet for Viking Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 248 | 202 | 155 | 362 | 903 |
| Prepaid Expenses | |||||
| Total Current Assets | 256 | 211 | 167 | 367 | 907 |
| Net Property, Plant And Equipment | 0.321 | 0.025 | 1.42 | 1.13 | 1 |
| Other Long Term Assets | |||||
| Total Assets | 257 | 211 | 169 | 368 | 908 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 12.1 | 8.78 | 21.9 | 19.1 | 27.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.2 | 8.78 | 23.2 | 20.1 | 28 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 244 | 202 | 145 | 348 | 880 |
| Total Liabilities & Shareholders' Equity | 257 | 211 | 169 | 368 | 908 |
| Total Common Shares Outstanding |